Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The Weight Management segment represents approximately 31.2% of market revenue in 2025 but is growing significantly faster at a projected CAGR of 19.4% versus 14.8% for Diabetes Treatment, driven by Wegovy's expanding global approvals and the SELECT trial's cardiovascular label update
Patients should be equipped with resources and knowledge about communication with healthcare providers, available support systems, and lifestyle modifications necessary for the success of their treatment
Phase 2 trial data showed up to 24 percent weight loss at 48 weeks, suggesting even more potent effects than either semaglutide or tirzepatide alone
It helps to know how these differ so you can respond appropriately
US$ 20.12
US$ 24.85
US$ 26.83
